流感疫苗接种人群感染COVID-19的结果:卡塔尔世界杯8强波胆分析基于人群的初级卫生保健电子记录队列研究%A Giner-Soriano,Maria %A de Dios,Vanessa %A Ouchi,Dan %A Vilaplana-Carnerero,Carles %A Monteagudo,Mònica %A Morros,Rosa %+ Fundació雷切尔卡大学研究所'Atenció Primària Salut Jordi Gol i Gurina (IDIAPJGol)， Gran Via de les Corts Catalanes 587， àtic，巴塞罗那，08007，西班牙，34 934824110，mginer@idiapjgol.info %K SARS-CoV-2 %K COVID-19 %K流感疫苗%K肺炎%K电子健康记录%K初级卫生保健%K疫苗接种%K公共卫生%K队列研究%K流行病学%K ehealth %K健康结局%K死亡率%D 2022 %7 11.11.2022 %9原文%J JMIR公共卫生监测%G英文%X由于对SARS-CoV-2的免疫力增强，以前曾提出流感免疫与对COVID-19感染并发症的易感性之间可能存在联系。目的:本研究旨在调查COVID-19患者是否可以从接种流感疫苗中受益。我们假设以前接种流感疫苗产生的免疫力会增强对SARS-CoV-2的部分免疫力。方法:我们进行了一项基于人群的队列研究，包括在西班牙加泰罗尼亚第一波COVID-19大流行期间(2020年3月1日至6月30日)在初级卫生保健(PHC)电子记录中登记的所有COVID-19患者。我们比较了在感染COVID-19之前接种流感疫苗的个体和未接种流感疫苗的个体。数据来自初级保健研究信息系统，获取了加泰罗尼亚580万人的初级保健信息。随访期间评估的主要结局是肺炎诊断、住院和死亡率。 Results: We included 309,039 individuals with COVID-19 and compared them on the basis of their influenza immunization status, with 114,181 (36.9%) having been vaccinated at least once and 194,858 (63.1%) having never been vaccinated. In total, 21,721 (19%) vaccinated individuals and 11,000 (5.7%) unvaccinated individuals had at least one of their outcomes assessed. Those vaccinated against influenza at any time (odds ratio [OR] 1.14, 95% CI 1.10-1.19), recently (OR 1.13, 95% CI 1.10-1.18), or recurrently (OR 1.10, 95% CI 1.05-1.15) before being infected with COVID-19 had a higher risk of presenting at least one of the outcomes than did unvaccinated individuals. When we excluded people living in long-term care facilities, the results were similar. Conclusions: We could not establish a protective role of the immunity conferred by the influenza vaccine on the outcomes of COVID-19 infection, as the risk of COVID-19 complications was higher in vaccinated than in unvaccinated individuals. Our results correspond to the first wave of the COVID-19 pandemic, where more complications and mortalities due to COVID-19 had occurred. Despite that, our study adds more evidence for the analysis of a possible link between the quality of immunity and COVID-19 outcomes, particularly in the PHC setting. %M 36 %R 10.2196/36712 %U https://publichealth.www.mybigtv.com/2022/11/e36712 %U https://doi.org/10.2196/36712 %U http://www.ncbi.nlm.nih.gov/pubmed/36